Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × Idarubicin × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 15 Myelodysplastic Syndromes 5 Leukemia, Biphenotypic, Acute 3 Leukemia, Myelomonocytic, Chronic 2 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Leukemia 1 Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 24 atezolizumab 19 durvalumab 18 Specimen Handling 15 pembrolizumab 12 lenvatinib 11 Magnetic Resonance Spectroscopy 11 tremelimumab 10 Nivolumab 10 Sorafenib 8 Radiosurgery 8 Cyclophosphamide 6 camrelizumab 5 apatinib 5 Ipilimumab 5 tislelizumab 4 regorafenib 4 fludarabine 4 cabozantinib 4 X-Rays 4 Immunoglobulin G 4 sintilimab 3 gadolinium ethoxybenzyl DTPA 3 Immune Checkpoint Inhibitors 3 Ethiodized Oil 3 E-7386 3 Disulfides 3 Blood Specimen Collection 3 Biopsy 3 gadobutrol 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03727633 2026-01-05

LIDA-BII

University Hospital, Montpellier

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡